Free tool
FAERS Monitor: Cabenuva Kit
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212888 or its brand name (Cabenuva Kit, Cabotegravir, Rilpivirine). Reports on generic versions are filed under their own applications.
Reports
6,543
Serious
1,293
20% of reports
Hospitalization
269
Death reported
123
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product dose omission issue722
- injection site pain669
- viral load increased514
- off label use478
- product use in unapproved therapeutic environment459
- virologic failure434
- pathogen resistance323
- pain304
- product complaint218
- exposure during pregnancy208
- injection site nodule203
- blood hiv rna increased197
- product storage error190
- inappropriate schedule of product administration186
- viral mutation identified160
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 205 |
| 2022 | 829 |
| 2023 | 1,276 |
| 2024 | 1,500 |
| 2025 | 1,515 |
| 2026 | 1,215 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,616 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product use in unapproved therapeutic environmentSignal | 459 | 3557.9 | 3122.5 | 773,333 |
| viral load increasedSignal | 514 | 490.3 | 448.3 | 217,425 |
| blood hiv rna increasedSignal | 197 | 391.7 | 338.5 | 68,090 |
| virologic failureSignal | 434 | 282.1 | 256.5 | 111,533 |
| viral mutation identifiedSignal | 160 | 145.9 | 124.8 | 21,896 |
| pathogen resistanceSignal | 323 | 118.1 | 105.9 | 36,065 |
| injection site noduleSignal | 203 | 60.4 | 52.7 | 11,586 |
| product complaintSignal | 218 | 27.9 | 24.5 | 5,583 |
| exposure during pregnancySignal | 208 | 10.8 | 9.4 | 1,837 |
| product dose omission issueSignal | 722 | 7.9 | 7.4 | 4,402 |
| injection site painSignal | 669 | 7.0 | 6.5 | 3,494 |
| product storage errorSignal | 190 | 7.0 | 6.1 | 971 |
| inappropriate schedule of product administrationSignal | 186 | 3.3 | 2.9 | 302 |
| off label use | 478 | 1.8 | 1.6 | 161 |
| pain | 304 | 1.6 | 1.4 | 68 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.